Option Care Health holds a Strong Buy rating from analysts, with 11 of 12 firms recommending purchase of the stock. The consensus price target of $39.82 implies 11.6% upside from the current price of ...
While its "AAA" credit rating, robust free cash flow, and low-debt profile offer a defensive haven in a volatile market, the ...
Hosted on MSN
Option Care Health raises 2025 revenue midpoint to $5.625B amid biosimilar headwinds and clinical expansion
Management projected full-year 2025 revenue of $5.6 billion to $5.65 billion, adjusted EBITDA of $468 million to $473 million, and adjusted EPS of $1.68 to $1.72. Sethna said, "We continue to expect ...
Ustekinumab had a market value of approximately $17.1 billion for the 12 months ending December 2024, per IQVIA. Hikma is acquiring Insys' unit dose nasal and sublingual spray manufacturing equipment, ...
Johnson & Johnson JNJ, through its Innovative Medicine segment, commercializes multiple blockbuster therapies spanning a wide range of disease areas, such as neuroscience, cardiovascular and metabolic ...
Johnson & Johnson JNJ has one of the most diverse revenue streams in the industry within its pharmaceuticals division, called Innovative Medicine. The company has several multi-million-dollar drugs ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results